Search - tctmd.com

Displaying 221 - 240 of 1857

Sort: Relevancy | Date

News Conference News EuroPCR 2023

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

Michael O'Riordan

May 18, 2023

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

L.A. McKeown

May 12, 2023

News Daily News

Enough PCI ‘Versus’ CABG—Time to Focus on Understudied Groups

Michael O'Riordan

May 09, 2023

News Daily News

Swedish Study Adds to Evidence That Beta-blockers May Not Be Needed Long After MI

Todd Neale

May 05, 2023

News Daily News

Oxidized Phospholipids and Lp(a) Strongly Associated With MACE: CASABLANCA

Michael O'Riordan

May 03, 2023

News Daily News

Aging, Angina, and Invasive Management: Some Nuance From ISCHEMIA

Shelley Wood

April 25, 2023

News Daily News

A Bivalirudin Rebuttal: ‘Some Issues’ to Discuss With BRIGHT-4

Shelley Wood

April 14, 2023

News Daily News

Moderate-Intensity Exercise Possible For Patients With Statin Side Effects

Michael O'Riordan

April 03, 2023

News Daily News

Physiologic Testing May ID Patients Who’ll Still Have Angina After PCI

Michael O'Riordan

March 31, 2023

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

News Conference News ACC 2023

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Caitlin E. Cox

March 14, 2023

News Conference News ACC 2023

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Michael O'Riordan

March 13, 2023

News Conference News ACC 2023

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

Todd Neale

March 10, 2023

News Conference News ACC 2023

MASTER@HEART: Long-term Endurance Athletes Not Immune to Atherosclerosis

Michael O'Riordan

March 10, 2023

News Conference News ACC 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Yael L. Maxwell

March 09, 2023

News Conference News ACC 2023

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

Michael O'Riordan

March 09, 2023

News Conference News ACC 2023

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Michael O'Riordan

March 06, 2023

Presentation ACC 2023

Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease: a Multimodality Imaging Study (YELLOW III)

Presenter: Annapoorna S. Kini

March 06, 2023

Presentation ACC 2023

Complete Revascularization Strategies in Patients Presenting With Acute Coronary Syndrome and Multivessel Coronary Disease

Presenter: Roberto Diletti

March 05, 2023

News Conference News ACC 2023

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Shelley Wood

March 04, 2023

Advertisement

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

Enough PCI ‘Versus’ CABG—Time to Focus on Understudied Groups

Swedish Study Adds to Evidence That Beta-blockers May Not Be Needed Long After MI

Oxidized Phospholipids and Lp(a) Strongly Associated With MACE: CASABLANCA

Aging, Angina, and Invasive Management: Some Nuance From ISCHEMIA

A Bivalirudin Rebuttal: ‘Some Issues’ to Discuss With BRIGHT-4

Moderate-Intensity Exercise Possible For Patients With Statin Side Effects

Physiologic Testing May ID Patients Who’ll Still Have Angina After PCI

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

MASTER@HEART: Long-term Endurance Athletes Not Immune to Atherosclerosis

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease: a Multimodality Imaging Study (YELLOW III)

Complete Revascularization Strategies in Patients Presenting With Acute Coronary Syndrome and Multivessel Coronary Disease

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content